AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9745160
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: omeprazole 20 mg plus clarithromycin 500 mg twice a day and amoxicillin 500 mg four times a day for 14 days
Trial: 9745160
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: omeprazole 20 mg, clarithromycin 250 mg and metronidazole 500 mg twice a day for seven days
Trial: 7990079
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II (5 ng/kg/min) infusion for three hours
Trial: 3198000
Drug: ICS 205-930,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS 205-930, 20 mg
Trial: 3198000
Drug: ICS 205-930,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS 205-930, 10 mg
Trial: 30213849
Drug: 89Zr-deferoxamine-ZEGFR:03115 (2.4-3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 89Zr-deferoxamine-ZEGFR:03115 (2.4-3.6 MBq, 2 μg) co-injected with 10 μg of nonlabeled ZEGFR:03115
Trial: 30213849
Drug: 18F-aluminium fluoride-NOTA-ZEGFR:03115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-aluminium fluoride-NOTA-ZEGFR:03115 (12 μg, 1.5-2 MBq/mouse)
Trial: 25319131
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment (US) at 1 MHz, intensity of 1.5 W/cm², continuous mode, applied five times a week for 2 weeks
Trial: 25319131
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) at 0.8 J/cm² with 905 nm wavelength, applied five times a week for 2 weeks
Trial: 20921291
Drug: Calcitriol with
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol with lanthanum carbonate (3000 mg/day)
Trial: 20921291
Drug: Calcitriol with
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol with sevelamer carbonate (7200 mg/day)
Trial: 15127672
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics as recommended by National Institute for Clinical Excellence guidelines
Trial: 3898818
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg at night (hs)
Trial: 3898818
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily (bid)
Trial: 29468383
Drug: Oral levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levocarnitine solution (50-100 mg/kg/day)
Trial: 29468383
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (oral hydrochlorothiazide, enalapril, spironolactone; digoxin for NYHA grade IV; dopamine and dobutamine for intractable heart failure; metoprolol when cardiac function restored to NYHA grade II-III)
Trial: 22331280
Drug: Experimental muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental muscle pain (induced by intramuscular injections of hypertonic (6%) saline)
Trial: 22331280
Drug: Control (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (isotonic (0.9%) saline injections)
Trial: 20565454
Drug: IK-1001 (Na2S)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IK-1001 (Na2S) 0.005-0.20 mg kg(-1), i.v., infused over 1 min
Trial: 17077114
Drug: Subtenon injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subtenon injection of triamcinolone acetonide (TA) before laser grid pattern photocoagulation (G‐PC)
Trial: 17077114
Drug: Laser grid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser grid pattern photocoagulation (G‐PC) without TA injection
Trial: 17077114
Drug: Subtenon injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subtenon injection of triamcinolone acetonide (TA) before G‐PC
Trial: 15995772
Drug: Periocline administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periocline administered subgingivally at baseline and weeks 1 to 4
Trial: 11955734
Drug: Combined radiotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined radiotherapy and adjuvant chemotherapy (9 weekly cycles of 24-h infusional chemotherapy: 20 mg/m² cisplatin, 2,200 mg/m² 5-fluorouracil, and 120 mg/m² leucovorin) after RT
Trial: 11955734
Drug: Radiotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy alone (35-40 fractions, 1.8-2.0 Gy/fraction/day, 5 days/week, total dose 70-72 Gy)
Trial: 8568015
Drug: Nefazodone single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone single daily doses (5-500 mg)
Trial: 8568015
Drug: Nefazodone multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone multiple daily doses (5 mg or 10 mg 3 times a day to a maximum of 500 mg 3 times a day)
Trial: 8568015
Drug: Nefazodone maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone maximum tolerated level (up to 1350 mg total daily dose)
Trial: 97474
Drug: Monthly interviews
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly interviews
Trial: 23444007
Drug: Free drug
RxNorm normalized name: sumatriptan 6 MG per 0.5 ML Needle-Free Drug Delivery System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free drug samples
Trial: 16778712
Drug: Caffeine 300
RxNorm normalized name: caffeine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 300 mg/d for 11 days
Trial: 16778712
Drug: Fluvoxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50 mg single oral dose)
Trial: 12959287
Drug: Tablet (155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet (155 mg rac‐hydroxychloroquine)
Trial: 12959287
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution (155 mg rac‐hydroxychloroquine)
Trial: 3040923
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy (CAV and VP-16/cisplatin for six cycles)
Trial: 3040923
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy (three cycles of CAV followed by three of VP-16/cisplatin)
Trial: 22500385
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Chinese medicine)
Trial: 17591031
Drug: d4T40 arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: d4T40 arm (stavudine 40 mg twice daily)
Trial: 17591031
Drug: d4T30 arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: d4T30 arm (stavudine 30 mg twice daily)
Trial: 29248604
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy intervention (group 3)
Trial: 27491025
Drug: Everolimus plus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus plus reduced-dose cyclosporine (EVR group)
Trial: 27491025
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil plus standard-dose cyclosporine (STD group)
Trial: 24631948
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (platinum-based, primarily single-agent carboplatin)
Trial: 20729740
Drug: Pegylated-interferon and
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated-interferon and ribavirin treatment
Trial: 8989060
Drug: Salm-1 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salm-1 (50 micrograms of salmeterol, single dose)
Trial: 8989060
Drug: Salm-2 (regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salm-2 (regular treatment with salmeterol for 1 week)
Trial: 8989060
Drug: Plac-1 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plac-1 (single dose of placebo)
Trial: 8989060
Drug: Plac-2 (regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plac-2 (regular treatment with placebo for 1 week)
Trial: 1455910
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms of vaccine
Trial: 1455910
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms of vaccine
Trial: 1455910
Drug: 1000 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 micrograms of vaccine
Trial: 1455910
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of vaccine
Trial: 6365236
Drug: Clotrimazole 500
RxNorm normalized name: clotrimazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 500 mg tablet
Trial: 6365236
Drug: Isoconazole 300
RxNorm normalized name: Isoconazol
DrugBank: Isoconazole (DB08943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoconazole 300 mg tablets (2 tablets)
Trial: 28830742
Drug: Valacyclovir (1.5G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir (1.5G twice daily for 16 weeks)
Trial: 17920357
Drug: High clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High clopidogrel loading dose (>300 mg)
Trial: 17920357
Drug: Standard clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard clopidogrel loading dose (300 mg)
Trial: 12761725
Drug: Surgical therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapies (artificial sphincter procedures and dynamic graciloplasty)
Trial: 10761756
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m2 day 1, etoposide 120 mg/m2 day 1‐3 (bolus therapy)
Trial: 10761756
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of carboplatin 100 mg/m2/week for six weeks (infusional therapy)
Trial: 8968699
Drug: Test foods
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test foods producing a higher insulin response
Trial: 1598096
Drug: Recombinant tissue
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant tissue plasminogen activator (t-PA) (100 mg)
Trial: 19473596
Drug: Deferiprone tablet
RxNorm normalized name: Deferiprone Tablets
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone tablet (GPO‐L‐ONE, 500 mg, 3 tablets)
Trial: 17460145
Drug: Azathioprine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (75 to 100 mg/d)
Trial: 17273657
Drug: Oral polymyxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral polymyxin (2.5 mg/kg in 4 daily doses for 7 days)
Trial: 17273657
Drug: Oral polymyxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral polymyxin
Trial: 8795324
Drug: Ondansetron alone
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron alone (4 mg bolus and 0.13 mg.ml‐1 in the morphine solution)
Trial: 8795324
Drug: Droperidol alone
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droperidol alone (1.25 mg bolus and 0.05 mg.ml‐1 in the morphine solution)
Trial: 8795324
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (ondansetron and droperidol)
Trial: 1352331
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol maleate topically and acetazolamide 125 mg orally
Trial: 31569780
Drug: Comprehensive non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive non-surgical periodontal therapy (test group; n = 20)
Trial: 27053715
Drug: Zonisamide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide (300 mg/d)
Trial: 23428763
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of levobupivacaine
Trial: 23428763
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of levobupivacaine plus 8 mg of lornoxicam
Trial: 23428763
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of levobupivacaine plus 8 mg of lornoxicam and 8 mg of morphine
Trial: 20698715
Drug: Erigeron breviscapus
RxNorm normalized name: ERIGERON CANADENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erigeron breviscapus (EBHM) extract, 2 tablets three times a day for 6 months
Trial: 20698715
Drug: Placebo, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 tablets three times a day for 6 months
Trial: 15634721
Drug: 1-wk GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-wk GH replacement therapy (9.5 microg/kg.d)
Trial: 12890208
Drug: TL01 phototherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TL01 phototherapy and topical calcipotriol cream (50 microg g(‐1))
Trial: 12890208
Drug: TL01 phototherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TL01 phototherapy and topical emollient as placebo
Trial: 30470568
Drug: Duloxetine 60mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60mg/day + usual analgesic regimens
Trial: 30470568
Drug: Usual analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual analgesic regimens (morphine±acetaminophen±gabapentin)
Trial: 2699653
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg metoclopramide
Trial: 2699653
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg metoclopramide
Trial: 2699653
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage of cisplatin (70-100 mg/m2) or ethylenediamine platinum II malonate (800-900 mg/m2)
Trial: 2699653
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of metoclopramide
Trial: 27902522
Drug: Topical use
RxNorm normalized name: Psoralens for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical use of Petroselinum crispum (parsley)
Trial: 18990368
Drug: Antagonist multiple-dose
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antagonist multiple-dose protocol (n = 45)
Trial: 17175305
Drug: Calcineurin inhibitor-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin inhibitor-free (CNI) protocol
Trial: 17175305
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (tacrolimus, prednisone, mycophenolate mofetil)
Trial: 16464205
Drug: Pharmaceutical interventions;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical interventions; compliance with economic evaluation guidance
Trial: 16464205
Drug: Modeling approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modeling approach for pharmaceuticals; compliance with economic evaluation guidance
Trial: 2439815
Drug: Bopindolol 4
RxNorm normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bopindolol 4 mg
Trial: 2439815
Drug: Bopindolol 8
RxNorm normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bopindolol 8 mg
Trial: 27269306
Drug: Midazolam 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.05 mg/kg with 50% oxygen inhalation (group H)
Trial: 27269306
Drug: Midazolam 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.05 mg/kg with normal air inhalation (group N)
Trial: 25224360
Drug: eBST ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eBST ≥ 11.4 ng/ml
Trial: 22571978
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma insulin levels in men with nonamnestic or amnestic MCI
Trial: 22571978
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma insulin levels in women with amnestic MCI
Trial: 22571978
Drug: APOE ε4
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: APOE ε4 genotype influence on insulin levels
Trial: 19727797
Drug: L(-)-menthol (0.01%)
RxNorm normalized name: menthol 0.01 MG/MG
DrugBank: Levomenthol (DB00825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L(-)-menthol (0.01%)
Trial: 19727797
Drug: Orange-flavoured placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange-flavoured placebo solution
Trial: 18922850
Drug: Hyperbaric articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric articaine 84 mg
Trial: 18922850
Drug: Plain articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain articaine 84 mg
Trial: 16268751
Drug: General guideline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General guideline implementation (education about guideline‐based drug recommendations)
Trial: 2354690
Drug: Low-dose iron
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose iron supplements (18-20 mg iron/d) containing haem iron and non-haem iron
Trial: 2354690
Drug: Low-dose iron
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose iron supplements (18-20 mg iron/d) containing non-haem iron only
Trial: 2354690
Drug: All low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All low-dose iron supplements
Trial: 2354690
Drug: None of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: None of the supplements
Trial: 6781157
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment with beta-receptor blocker propranolol, alone or in combination with dihydralazine and/or hydrochlorothiazide for 8 years.
Trial: 31464577
Drug: Intradiscal platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal platelet-rich plasma (PRP) injections
Trial: 17334144
Drug: Topical negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical negative pressure
Trial: 15728930
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) at 80 ppm for 72 hours
Trial: 15728930
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for pulmonary tuberculosis
Trial: 11849632
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (Triphasil)
Trial: 10516746
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment (698 patients)
Trial: 10516746
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment in patients >/=60 years
Trial: 10516746
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment in patients <60 years
Trial: 10516746
Drug: Conventional combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional combined chemotherapy in patients >/=60 years
Trial: 8592718
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) referral
Trial: 8592718
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy implementation within 1 month of back injury
Trial: 8592718
Drug: Timing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timing of physical therapy
Trial: 2013419
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily with NSAID treatment
Trial: 2013419
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily without NSAID treatment